Henry Rosevear, MD
Dr. Rosevear, a member of the Urology Times Clinical Practice Board, is in private practice at Pikes Peak Urology, Colorado Springs, CO.
MOC: Members of the UT editorial board weigh in
In conjunction with Urology Times' recent coverage of maintenance of certification (MOC), we asked several members of the UT Editorial Advisory Board to weigh in with their thoughts on MOC.
The return of prostate cancer: A step backward
Urologist Henry Rosevear, MD discusses his thoughts on PSA screening and the recent increase in patients presenting with metastatic disease.
My $4.07 check from an insurer: A sign of the times
My $4.07 check from an insurer: A sign of the times
Urologist Henry Rosevear, MD, recalls some of his experiences working with government-sponsored health care programs.
The transgender community: Urology has a role and responsibility
"The fear of a hypothetical situation should not be used to place restrictions on the life of one of our transgender patients," writes Henry Rosevear, MD.
AUA 2016: Reflections on mentors, MRI fusion, and more
The AUA annual meeting provided learning experiences for Henry Rosevear, MD, on multiple levels. Here are eight observations he brought home from San Diego.
Marijuana and me: A Colorado urologist’s experience
"I have no personal experience with marijuana. But I do practice medicine in Colorado and given the state’s ongoing experiment with legal recreational marijuana, I am accumulating a significant amount of professional experience with the drug," writes Henry Rosevear, MD.
Do you ERAS? The future of post-cystectomy care
Henry Rosevear, MD, discusses Enhanced Recovery After Surgery, a protocol that allows urologists in the trenches to provide excellent perioperative care.
AUA 2016 checklist: 10 ways to maximize the meeting
Urologist Henry Rosevear, MD, has put together a brief checklist for first-time attendees—and for veteran attendees as well.
Out-of-control drug pricing requires creative solutions
Urologists have direct experience with drug shortages and their impact on pricing, thanks to the recent shortage of BCG. A sudden hike in the price of a competing generic drug seemed to be no coincidence, Henry Rosevear, MD, writes. He ponders a few similar, troubling cases and some proposed solutions.